URB1 Antibody

What is URB1 and why is it significant in research?

URB1 (also known as Nucleolar pre-ribosomal-associated protein 1 or NPA1) is an essential ribosome assembly factor involved in ribosome biogenesis. It associates with Urb2 and five other ribosome assembly factors (RAFs) to form a low-molecular-mass complex involved in the early steps of 60S ribosomal subunit assembly . Its significance extends beyond ribosome assembly, as it has been implicated in colorectal cancer (CRC) pathogenesis and may represent a potential therapeutic target . URB1 frameshift mutations resulting in complete loss-of-function have been shown to cause embryonic lethality in pigs, underscoring its essential role in development .

What are the key gene ontology annotations for URB1?

URB1 gene ontology annotations primarily relate to ribosomal RNA processing functions, including:

• Maturation of 5.8S rRNA from tricistronic rRNA transcript (SSU-rRNA, 5.8S rRNA, LSU-rRNA)

• Maturation of LSU-rRNA from tricistronic rRNA transcript (SSU-rRNA, 5.8S rRNA, LSU-rRNA)

These functions highlight URB1's critical role in ribosome biogenesis pathways and RNA processing machinery.

What alternative nomenclature should researchers be aware of when searching literature on URB1?

When conducting literature searches, researchers should be aware of several alternative names for URB1:

Protein Aliases:

• Nucleolar pre-ribosomal-associated protein 1

• Nucleolar preribosomal-associated protein 1

• Nucleolar protein 254 kDa

• Protein URB1

• URB1 ribosome biogenesis 1 homolog

Gene Aliases:

• C21orf108

• KIAA0539

• NOP254

• NPA1

Using these alternative names in literature searches will ensure comprehensive coverage of relevant research.

What evidence supports URB1's role in colorectal cancer?

Current research demonstrates that URB1 is upregulated in colorectal cancer (CRC) tissues compared to normal tissues, with expression correlating with clinicopathological characteristics. Functional studies have shown that silencing URB1 significantly hampers human CRC cell proliferation and growth both in vitro and in vivo, suggesting an oncogenic role . The mechanism appears to involve XBP1-mediated transcriptional activation of ATF4, with downstream effects on cell cycle regulation through CCNA2 (cyclin A2) . These findings collectively position URB1 as a potential therapeutic target for CRC treatment strategies.

How does URB1 interact with the ATF4 signaling pathway in cancer cells?

URB1 contributes to oncogenesis through a pathway involving XBP1-mediated transcriptional activation of ATF4. Research has demonstrated that:

• Silencing URB1 significantly decreases ATF4 and cyclin A2 (CCNA2) expression in CRC cells both in vivo and in vitro

• Restoration of ATF4 effectively reverses the malignant proliferation phenotype in URB1-silenced CRC cells

• XBP1 transcriptionally activates ATF4 by binding to its promoter region, as confirmed by dual-luciferase reporter and ChIP assays

• XBP1 colocalizes with ATF4 in the nuclei of RKO cells

This signaling axis (URB1→XBP1→ATF4→CCNA2) represents a potential intervention point for targeted therapies in CRC.

What factors should be considered when selecting a URB1 antibody for research?

When selecting a URB1 antibody, researchers should consider:

• Specificity: Confirm the antibody specifically detects endogenous levels of total URB1 protein with minimal cross-reactivity

• Applications validated: Verify the antibody is validated for your intended application (e.g., IHC, ICC/IF, IHC-P)

• Species reactivity: Most commercial URB1 antibodies are validated for human samples

• Immunogen information: Consider whether the antibody was raised against a synthetic peptide (often C-terminal) or recombinant protein fragment

• Clonality: Most available URB1 antibodies are rabbit polyclonal antibodies

• Supporting validation data: Review available immunohistochemistry or other application images provided by manufacturers

These considerations will help ensure selection of an appropriate antibody for specific research applications.

What validation methods should be employed to confirm URB1 antibody specificity?

To ensure URB1 antibody specificity, researchers should implement multiple validation approaches:

• Positive and negative controls: Use tissues/cells known to express or lack URB1

• Multiple antibody validation: Compare results using different antibodies targeting distinct URB1 epitopes

• Knockout/knockdown verification: Validate specificity using URB1 knockdown samples (e.g., shRNA-transfected cells as described in reference )

• Peptide competition assay: Pre-incubate the antibody with immunogen peptide to confirm signal elimination

• Western blot analysis: Confirm detection of a band at the expected molecular weight (~254 kDa)

• Cross-platform validation: Compare results across multiple detection methods (e.g., IHC, western blot, IF)

Thorough validation improves experimental reliability and reproducibility when working with URB1 antibodies.

What are the optimal immunohistochemistry protocols for URB1 detection in tissue samples?

For optimal URB1 detection in paraffin-embedded tissues, researchers should consider this general protocol framework:

• Antibody dilution: Use URB1 antibody at 1:20-1:50 dilution range for IHC-P applications

• Antigen retrieval: Heat-induced epitope retrieval in citrate buffer (pH 6.0) is typically effective

• Detection system: Use appropriate secondary antibodies conjugated to HRP or other detection systems

• Counterstaining: Hematoxylin provides effective nuclear counterstaining

• Scoring method: Follow established pathological assessment methods - negative (no or weak staining) versus positive (distinct or strong staining in >20% of cells)

For tissue microarray analysis of URB1 expression, researchers should have experienced pathologists evaluate staining intensity and percentage of positively stained cells, preferably blinded to experimental conditions .

How can URB1 antibodies be utilized in experimental models of colorectal cancer?

URB1 antibodies can be employed in CRC research through multiple experimental approaches:

• Expression analysis in clinical samples: Evaluate URB1 protein levels in CRC tissues versus adjacent normal tissues using IHC with tissue microarrays

• Correlation with clinicopathological features: Analyze associations between URB1 expression and tumor stage, grade, and patient outcomes

• Validation of knockdown efficiency: Confirm URB1 silencing in shRNA experiments through western blot analysis

• Xenograft tumor models: Evaluate URB1, ATF4, and CCNA2 expression in tumor xenografts following URB1 manipulation

• Colocalization studies: Investigate URB1 interactions with other proteins (e.g., XBP1, ATF4) through immunofluorescence co-staining

These applications provide insights into URB1's role in CRC pathogenesis and potential therapeutic targeting.

What approaches can resolve contradictory results when measuring URB1 expression across different detection methods?

When facing contradictory URB1 detection results, implement these systematic troubleshooting steps:

• Antibody epitope consideration: Different antibodies target different URB1 epitopes - compare immunogen sequences between antibodies

• Isoform-specific detection: Determine if contradictions stem from differential detection of URB1 isoforms

• Sample preparation variables: Standardize fixation methods, antigen retrieval, and protein extraction protocols

• Quantification methodologies: Implement consistent scoring/quantification methods for IHC (e.g., pathologist-blinded evaluation)

• Cross-validation with mRNA expression: Correlate protein detection with URB1 mRNA expression analysis

• Bioinformatic analysis: Integrate findings with public database information (e.g., The Cancer Genome Atlas)

This systematic approach helps resolve contradictions and establish reliable URB1 detection methodologies.

How can researchers optimize co-immunoprecipitation experiments to study URB1 interactions with binding partners?

To optimize co-immunoprecipitation of URB1 and potential interaction partners:

• Lysis buffer optimization: Use buffers that preserve nuclear protein interactions (URB1 is a nucleolar protein)

• Antibody selection: Choose URB1 antibodies validated for immunoprecipitation applications

• Pre-clearing strategy: Implement thorough pre-clearing to reduce non-specific binding

• Crosslinking considerations: Evaluate whether formaldehyde crosslinking improves detection of transient interactions

• Specific controls: Include IgG control and input controls for accurate interpretation

• Detection strategy: For investigating interactions with XBP1 or ATF4, use reciprocal co-IPs with antibodies against these proteins

• Validation through alternative methods: Confirm interactions using proximity ligation assays or FRET

These optimizations will enhance detection of genuine URB1 protein-protein interactions in research settings.

What are the most effective approaches for URB1 gene silencing in experimental systems?

Based on published research methodologies, effective URB1 silencing can be achieved through:

• shRNA lentiviral vectors: Use targeting sequences that have demonstrated effective knockdown in CRC cell lines such as RKO and HCT116

• Verification of knockdown: Confirm silencing efficiency through both:

  • Western blot analysis for protein reduction

  • qRT-PCR for mRNA reduction

• Phenotypic confirmation: Verify functional consequences of URB1 silencing through:

  • Cell proliferation assays

  • Colony formation assays

  • Cell cycle analysis

  • Xenograft tumor formation

• Rescue experiments: Implement ATF4 restoration in URB1-silenced cells to confirm mechanistic relationships

These approaches have successfully demonstrated URB1's functional significance in cancer research models.

What experimental design best demonstrates the relationship between URB1 and downstream targets in cancer pathways?

To effectively demonstrate URB1's relationship with downstream targets (e.g., XBP1, ATF4, CCNA2), implement this experimental workflow:

• Initial screening: Use microarray analysis to identify differentially expressed genes between URB1-silenced and control cells

• Bioinformatic analysis: Apply tools like Ingenuity Pathway Analysis (IPA) and JASPAR to predict regulatory relationships

• Validation experiments:

  • Confirm protein expression changes by western blot

  • Verify mRNA expression changes by qRT-PCR

  • Demonstrate transcriptional regulation through luciferase reporter assays

  • Confirm direct binding using ChIP assays

• Functional relationship testing:

  • Perform rescue experiments (e.g., restoring ATF4 expression in URB1-silenced cells)

  • Evaluate phenotypic outcomes (proliferation, colony formation)

• In vivo validation: Confirm pathway relationships in xenograft models through IHC staining for URB1, ATF4, CCNA2, and proliferation markers

This comprehensive approach provides multiple lines of evidence for URB1's regulatory relationships in cancer pathways.